Eledon Pharmaceuticals, Inc. (ELDN) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 67.89M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | (m) | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $67.89M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $69.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $66.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $66.70M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $68.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $58.09M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $51.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $41.10M | (m) | (m) | $-56.22M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $32.51M | (m) | (m) | $-46.91M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $29.61M | (m) | (m) | $-42.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $30.31M | (m) | (m) | $-43.00M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $30.50M | (m) | (m) | $-91.35M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $30.02M | (m) | (m) | $-90.75M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $28.56M | (m) | (m) | $-89.68M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $27.08M | (m) | (m) | $-88.43M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $26.01M | (m) | (m) | $-39.13M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $26.22M | (m) | (m) | $-39.03M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $24.72M | (m) | (m) | $-37.72M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $23.73M | (m) | (m) | $-36.87M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $20.59M | (m) | (m) | $-33.83M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $13.55M | (m) | (m) | $-29.47M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $10.14M | (m) | (m) | $-24.09M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $6.13M | (m) | (m) | $-18.46M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $4.43M | (m) | (m) | $-16.28M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $5.32M | (m) | (m) | $-13.06M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $6.79M | (m) | (m) | $-14.55M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $8.13M | (m) | (m) | $-16.05M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $9.54M | (m) | (m) | $-16.46M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $9.68M | (m) | (m) | $-17.04M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $8.71M | (m) | (m) | $-16.14M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $6.82M | (m) | (m) | $-14.06M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $4.57M | (m) | (m) | $-11.59M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $3.44M | (m) | (m) | $-11.05M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $2.64M | (m) | (m) | $-14.53M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $2.02M | (m) | (m) | $-13.12M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $24.22M | (m) | (m) | $-45.48M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $24.75M | (m) | (m) | $-44.13M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $17.40M | (m) | (m) | $-30.54M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $25.02M | $0.00 | (m) | $-38.12M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $31.72M | (m) | (m) | $-45.44M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $34.05M | (m) | (m) | $-48.03M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $30.01M | (m) | (m) | $-43.44M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $32.64M | $0.00 | (m) | $-45.26M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $28.71M | (m) | (m) | $-40.45M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $23.04M | (m) | (m) | $-34.97M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $21.58M | (m) | (m) | $-31.87M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $14.58M | (m) | $2.11M | $-23.46M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | $-19.69M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | $-18.25M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $12.20M | (m) | $238.00K | $-15.75M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $7.37M | (m) | $210.00K | $-9.65M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |